CureVac (CVAC) Stock Price, News & Analysis

Company Overview

CureVac N.V. (NASDAQ: CVAC) is a clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, specializing in the development of messenger RNA (mRNA)-based therapeutics and vaccines. The company’s proprietary mRNA technology platform is designed to harness the body’s natural cellular machinery to produce proteins that address a wide range of diseases. Since its founding in 2000, CureVac has focused on optimizing mRNA stability, delivery and manufacturing processes to create modular drug candidates that can be rapidly designed and scaled.

The company’s product pipeline spans both prophylactic and therapeutic applications. In infectious diseases, CureVac is advancing vaccine candidates targeting pathogens such as rabies and influenza, leveraging its mRNA platform for rapid response and dose sparing. In oncology, it is developing individualized cancer immunotherapies that direct the immune system to recognize and eliminate tumor cells. Additional programs are exploring mRNA-based treatments for rare diseases and soluble protein replacement therapies.

CureVac operates collaboration and partnership agreements with global pharmaceutical and biotechnology firms to strengthen its R&D capabilities and expand manufacturing capacity. The company has established strategic alliances to support late-stage development and commercialization, including agreements for large-scale mRNA production in Europe and North America. This network of partnerships allows CureVac to accelerate clinical development timelines and prepare for potential global rollouts of its vaccine and therapeutic candidates.

Led by Chief Executive Officer Franz‐Werner Haas, CureVac’s management team combines expertise in molecular biology, clinical development and regulatory affairs. Over the past decade, the company has built a multidisciplinary workforce of scientists and engineers working at its research sites in Tübingen, Boston and other innovation hubs. As CureVac continues to advance its mRNA technology, it aims to deliver a new class of safe, effective and scalable treatments that address unmet medical needs worldwide.

Key Stats

• Today's Range: $5.39 to $5.43
• 50-Day Range: $3.37 to $5.60
• 52-Week Range: $2.37 to $5.72
• Volume: 1.01 million shs
• Average Volume: 778,986 shs
• Market Capitalization: $1.21 billion
• P/E Ratio: 5.86
• Dividend Yield: N/A
• Price Target: $6.83
• Consensus Rating: Hold

CureVac Stock Analysis - MarketRank™

CureVac scored higher than 81% of companies evaluated by MarketBeat, and ranked 184th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

CureVac has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

CureVac has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CureVac is 5.86, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of CureVac is 5.86, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.26.

Price to Book Value per Share Ratio

CureVac has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.93% of the float of CureVac has been sold short.

Short Interest Ratio / Days to Cover

CureVac has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CureVac has recently decreased by 65.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CureVac does not currently pay a dividend.

Dividend Growth

CureVac does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.9 / 5
• Environmental Score: -2.22

Percentage of Shares Shorted

0.93% of the float of CureVac has been sold short.

Short Interest Ratio / Days to Cover

CureVac has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CureVac has recently decreased by 65.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CureVac insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.15% of the stock of CureVac is held by insiders.

Percentage Held by Institutions

Only 17.26% of the stock of CureVac is held by institutions.

CVAC Stock Analysis - Frequently Asked Questions

How have CVAC shares performed this year?

CureVac's stock was trading at $3.41 on January 1st, 2025. Since then, CVAC shares have increased by 58.1% and is now trading at $5.39.

How were CureVac's earnings last quarter?

CureVac N.V. (NASDAQ:CVAC) announced its earnings results on Thursday, May, 22nd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.08. The business earned $0.94 million during the quarter, compared to analysts' expectations of $4.27 million. CureVac had a net margin of 35.44% and a trailing twelve-month return on equity of 30.89%.

When did CureVac IPO?

CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers.

Who are CureVac's major shareholders?

Top institutional investors of CureVac include Ballentine Partners LLC (0.02%), Signaturefd LLC (0.01%), Baron Wealth Management LLC (0.01%) and Kathmere Capital Management LLC.

How do I buy shares of CureVac?

Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CureVac own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA).

Company Calendar

• Last Earnings: 5/22/2025
• Today: 7/20/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CVAC
• CIK: 1809122
• Web: www.curevac.com
• Phone: 49-70-71988-30
• Fax: 49-7071-9883
• Employees: 880
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CureVac: $6.83
• High Price Target: $10.00
• Low Price Target: $5.00
• Potential Upside/Downside: +26.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.92
• Trailing P/E Ratio: 5.86
• Forward P/E Ratio: 7.49
• P/E Growth: N/A
• Net Income: $175.50 million
• Net Margins: 35.44%
• Pretax Margin: 39.67%
• Return on Equity: 30.89%
• Return on Assets: 25.54%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 7.65
• Quick Ratio: 7.64

Sales & Book Value

• Annual Sales: $579.18 million
• Price / Sales: 2.09
• Cash Flow: $0.87 per share
• Price / Cash Flow: 6.17
• Book Value: $3.36 per share
• Price / Book: 1.60

Miscellaneous

• Outstanding Shares: 224,340,000
• Free Float: 219,515,000
• Market Cap: $1.21 billion
• Optionable: Optionable
• Beta: 2.53